LS01™ + B632™ (BIFIASTHM)
Allergy & Immunology
Asthma
Modulates immunity in asthmatic subjects
Reduces asthma frequency and severity
1) LS01 1 billion CFU/ AFU + B632 1 billion CFU/AFU
Blend
Finished dosage form
1) Drago L., et al. The Probiotics in Pediatric Asthma Management (PROPAM) Study in the Primary Care Setting: A Randomized, Controlled, Double-Blind Trial with Ligilactobacillus salivarius LS01 (DSM 22775) and Bifidobacterium breve B632 (DSM 24706). J Immunol Res. 2022 Jan 17;2022:3837418. doi: 10.1155/2022/3837418.
2) Drago L. et al. A post hoc analysis on the effects of a probiotic mixture on asthma exacerbation frequency in schoolchildren. ERJ Open Res. 2022 May 9;8(2):00020-2022. doi: 10.1183/23120541.00020-2022.
3) Ciprandi G. et al. The PRObiotics in Pediatric Asthma Management (PROPAM) study: A post hoc analysis in preschoolers. Pediatr Pulmonol. 2022 May;57(5):1355-1357. doi: 10.1002/ppul.25878.
4) Ciprandi G, et al. The Probiotics in Pediatric Asthma Management (PROPAM) study: A Post Hoc analysis in allergic children. Ann Allergy Asthma Immunol. 2022 Jul;129(1):111-113. doi: 10.1016/j.anai.2022.04.026.
5) Ciprandi G, et al. Probiotics in Children with Asthma. Children (Basel). 2022 Jun 29;9(7):978. doi: 10.3390/children9070978.
